What is a tumor board and should my Melanoma case be reviewed by one
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Tumor Boards and Your Melanoma Care
What Is a Tumor Board?
A tumor board (also called a multidisciplinary tumor conference or case conference) is a meeting where a team of cancer specialists from different fields reviews individual patient cases together. Think of it as a "second opinion by committee" — rather than one doctor making decisions alone, multiple experts collaborate to discuss your diagnosis, test results, and treatment options.
Who's on a Tumor Board?
A typical melanoma tumor board includes:
- Dermatologists (skin specialists)
- Surgical oncologists (cancer surgeons)
- Medical oncologists (chemotherapy and systemic therapy specialists)
- Radiation oncologists (radiation therapy specialists)
- Pathologists (experts who examine tissue samples)
- Radiologists (imaging specialists)
- Nurses and other support staff
Each specialist brings their expertise to the discussion, which helps ensure comprehensive, coordinated care.
Should Your Melanoma Case Be Reviewed?
Yes — tumor board review is particularly valuable for melanoma patients, especially if:
✅ Your melanoma is stage 3 or stage 4 (regional or metastatic disease) ✅ Your case is complex (unusual features, multiple sites, or unclear treatment path) ✅ You're considering clinical trials or newer treatment approaches ✅ Your melanoma has recurred (come back after initial treatment) ✅ You have specific biomarkers like BRAF mutations that affect treatment options ✅ You want to ensure you're getting the most current, evidence-based care
According to the NCCN Guidelines for Patients: Melanoma (2025), multidisciplinary care coordination is emphasized throughout melanoma treatment planning, particularly for regional and metastatic disease where treatment decisions involve choosing between surgery, immunotherapy, targeted therapy, radiation, and other options.
Why Tumor Board Review Matters for Melanoma
Melanoma treatment has evolved significantly. The NCCN Guidelines emphasize that treatment decisions should consider:
- Your specific stage and tumor characteristics
- Biomarker testing results (like BRAF status)
- Whether your disease is resectable (surgically removable) or unresectable
- Multiple treatment modalities working together (surgery + immunotherapy, for example)
A tumor board ensures all these factors are weighed by experts who stay current with the latest research and treatment approaches.
How to Request Tumor Board Review
Ask your oncologist directly: "Would you recommend my case be reviewed by a tumor board?" or "Can my case be presented at your institution's tumor board?"
Most major cancer centers (including NCCN Cancer Centers) have regular tumor boards, and your care team can submit your case for review. This is typically done at no additional cost to you.
Questions to Ask Your Care Team
- Does your institution have a tumor board, and would my case benefit from review?
- When would my case be presented, and can I attend or receive a summary of the discussion?
- Are there any specific concerns about my case that would make tumor board review particularly helpful?
- How will the tumor board's recommendations be communicated to me?
- Will tumor board review affect my treatment timeline?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Source Guidelines
NCCN Guidelines for Patients: Melanoma (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with general for Melanoma patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: